inSili.com offers an elite source of technology and unique expertise for innovative pharmaceutical R&D.
We provide premier scientific consulting and technology services. Our clients are among the world's top biotech, pharmaceutical, chemical and cosmeceutical enterprises.
inSili.com's exclusive technology enables a rennaissance of small-molecule drug discovery and provides the foundation for custom-tailored medicines of the future.
inSili.com's founders created and defined the terms "scaffold-hopping" and "frequent-hitters" in drug discovery and developed groundbreaking algorithms like CATS (Chemically Advanced Template Search) and DOGS (Design Of Genuine Structures). Own technology development and drug discovery projects continuously strengthen inSili.com's unmatched track record.
We are specialized in low-data molecular discovery supported by collaborative artificial intelligence.
Our industry-proven CopyCATS™ and ShapeCATS™ virtual screening methods permit rapid discovery of new chemical entities with desired properties and target activities.
POOMA™ (PrOjection Of Molecular Attributes) software generates fitness landscapes for compound library design, and enables rapid data clustering for diversity analysis.
inSili.com's Collection Of Bioactive Reference Analogs (COBRA™) and unique macromolecular target prediction technique TIGER™ (Target Inference GEneRator) enable the deorphaning of drugs, bioactive natural products and phenotypic screening hits for compound library design, target-oriented hit-to-lead expansion, off-target analysis and drug re-purposing.
We develop artificial intelligence systems, enabling the discovery of bioactive chemical entities with desired properties.